POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE ANALYSES OF A PHASE 1 STUDY OF SUTIMLIMAB IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA.

被引：0
|
作者：
Chow, T. [1 ]
Daak, A. [1 ]
Lu, Q. [2 ]
Wong, N. [1 ]
机构：
[1] Sanofi, Waltham, MA USA
[2] Sanofi, Bridgewater, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-038
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [41] Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies
    Wang, Qi
    Banerjee, Kamalika
    Vasilinin, Grygoriy
    Marier, J. F.
    Gibbons, Jacqueline A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (05): : 748 - 762
  • [42] Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with moderately to severely active Ulcerative Colitis
    Thakre, N.
    Goebel, A.
    D'Cunha, R.
    Winzenborg, I.
    Liu, W.
    Pang, Y.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1831 - I1831
  • [43] Population pharmacokinetics and exposure-response analyses for efficacy and safety of apadacitinib in patients with axial Spondyloarthritis
    Bhatnagar, Sumit
    Eckert, Doerthe
    Stodtmann, Sven
    Song, In-Ho
    Wung, Peter
    Liu, Wei
    Mohamed, Mohamed-Eslam F.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (02):
  • [44] Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
    Thakre, Neha
    Goebel, Aline
    Winzenborg, Insa
    Suleiman, Ahmed A.
    D'Cunha, Ronilda
    Mensing, Sven
    Liu, Wei
    Pang, Yinuo
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (03) : 847 - 857
  • [45] A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis
    Dreesen, Erwin
    Kantasiripitak, Wannee
    Detrez, Iris
    Stefanovic, Sebastian
    Vermeire, Severine
    Ferrante, Marc
    Bouillon, Thomas
    Drobne, David
    Gils, Ann
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (04) : 570 - 580
  • [46] Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema
    Garcia, Ramon
    Cheng, Shen
    Glassman, Fiona
    Sharma, Ankur
    De Miguel-Lillo, Bernardo
    Wiens, Matthew
    Johnston, Curtis
    Lawo, John-Philip
    Pragst, Ingo
    French, Jonathan
    Polhamus, Dan
    Nandy, Partha
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025,
  • [47] Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
    Deng, Rong
    Gibiansky, Leonid
    Lu, Tong
    Flowers, Christopher R.
    Sehn, Laurie H.
    Liu, Qi
    Agarwal, Priya
    Liao, Michael Z.
    Dere, Randall
    Lee, Calvin
    Man, Gabriel
    Hirata, Jamie
    Li, Chunze
    Miles, Dale
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (06): : 1055 - 1066
  • [48] Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph plus chronic myeloid leukemia in chronic phase: Results from ENESTnd
    Hughes, T. P.
    le Coutre, P. D.
    Clark, R. E.
    Saglio, G.
    Larson, R. A.
    Yin, Q.
    Demirhan, E.
    Hoenekopp, A.
    Hochhaus, A.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome
    Marier, Jean-Francois
    Jomphe, Claudia
    Peyret, Thomas
    Wang, Yi
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06): : 2497 - 2509
  • [50] Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis
    Dale Miles
    Nelson L. Jumbe
    Steven Lacy
    Linh Nguyen
    Clinical Pharmacokinetics, 2016, 55 : 93 - 105
12345